BPC-157 Side Effects: Withdrawal and Discontinuation Syndrome

Does BPC-157 cause withdrawal when you stop it?

The human studies FDA reviewed and those in the 2026 systematic review did not report symptoms after BPC-157 was stopped, but they were not designed to test for withdrawal [1][2]. The systematic review searched to June 1, 2026 and found three human studies with 30 patients total: a knee-pain chart review, an interstitial cystitis pilot and a two-person intravenous safety pilot. All were of poor methodological quality, and certainty of evidence was rated very low [2]. FDA's own review also covered small enema studies, including a trial in 53 people with mild to moderate ulcerative colitis (BPC-157 enema 80 mg or placebo daily for 2 weeks) that exists only as a meeting abstract [1].

What the human studies measured

Knee pain. A retrospective chart review at one Florida clinic covered 17 patients, 16 of whom were reached by phone; 11 of the 12 given BPC-157 alone into the knee reported significant improvement. There was no control group, no validated outcome tool, results were recalled, and no adverse events were noted [3].

Interstitial cystitis. Twelve women who had not responded to pentosan polysulfate received a total of 10 mg injected around the bladder wall in one procedure; 10 of 12 reported complete symptom resolution and 2 of 12 about 80%. Single arm, no placebo, patient-rated, no adverse events reported [4].

Intravenous safety. Two adults received 10 mg on day 1 and 20 mg on day 2, with no measurable change in the tested heart, liver, kidney, thyroid or glucose markers and no side effects reported. With two people, the study cannot establish safety [5].

Pharmacokinetics and dosing

FDA found no human pharmacokinetic data for BPC-157 taken by mouth, injected under the skin, used as a nasal spray or applied to the skin. After rectal enemas in two early studies, BPC-157 was mostly not detectable in blood, so FDA judged it appears not to be absorbed systemically by that route [1].

There is also no approved dose. Doses in the small human reports (80 mg daily by enema for two weeks in ulcerative colitis, 2 to 4 mg injected into the knee, 10 mg into the bladder wall) are study doses, not recommended ones [1].

What has been reported with BPC-157

FDA's search of its adverse-event database through December 4, 2025 found three reports, all injectable BPC-157: injection-site redness and swelling lasting nine days in a patient who also used a compounded thymosin; shortness of breath leading to an emergency room visit; and widespread skin and gum darkening that recurred when the person was re-exposed to a BPC-157 plus TB-500 research product. FDA said it cannot tell whether BPC-157 caused these events [1].

In the small human studies FDA reviewed, no serious adverse events were reported, but the studies were short, small and gave limited safety information. In the healthy-volunteer enema studies (meeting abstracts), the most frequent events were headache and flatulence [1].